How long is Elaprase’s patent protection (“patent dauer”)?
“Elaprase” is the brand name for idursulfase, an enzyme replacement therapy. Patent protection duration depends on multiple layers of rights (the original composition and later improvement patents), plus each country’s rules for extensions. Because patent expiry is jurisdiction-specific and changes over time, the exact “Elaprase patent dauer” can’t be given precisely without knowing:
- Which country (e.g., US, EU/UK, Germany, Japan, etc.)
- Which specific patent number or product right you mean (original drug vs. formulation/process vs. new indications)
When does Elaprase go generic/biosimilar?
For enzyme replacement therapies like idursulfase, market entry is typically blocked until relevant compound and method-of-use patents expire, and sometimes until regulatory exclusivities also run out. The practical date people look for is the earliest expected launch date in a specific country after the last enforceable patent expires.
To determine that date, you need the country and the set of patents being asserted or used to block approval.
What determines the “end date” for an Elaprase patent?
Patent duration is affected by:
- The filing date of the specific patent (many patents expire ~20 years after the filing date, but that is not the final answer in every case).
- Patent term adjustments/extensions granted by that country.
- Whether there are multiple overlapping patents (so the “last one standing” controls market freedom).
- Litigation that can delay or accelerate outcomes.
- Any regulatory exclusivities that extend beyond patent expiry.
Which “Elaprase patent dauer” do you want: US, EU/UK, or somewhere else?
Reply with the country/region and (if you have it) the patent number or link you’re working from. Then I can translate it into a clear expiry/timeline for that specific right (and flag any common follow-on patents that affect generic/biosimilar entry).